Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the immunisation protects vulnerable infants

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”

The pregnancy vaccine operates by activating the mother’s body’s defences to generate protective antibodies, which are then passed to the foetus through the placenta. This mother-derived protection provides newborns with instant defence from the moment of birth, exactly when they are most vulnerable to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.

• Nearly 85 per cent protection when vaccinated 4 weeks before birth
• Maternal antibodies passed through placenta safeguard newborns from birth
• Coverage possible with two-week gap before premature birth
• Vaccination in third trimester still offers meaningful protection for infants

Strong evidence from current research

The effectiveness of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation conducted across England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month period, providing robust and representative information of the vaccine’s real-world impact. The study’s results have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scale of this research offers healthcare professionals and prospective parents with confidence in the vaccine’s demonstrated effectiveness across different groups and contexts.

The results present a striking picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This marked difference underscores the vaccine’s vital importance in reducing the risk of serious illness in newborns. The decrease in hospital admissions above 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.

Study methodology and scope

The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection levels and hospitalisations. The substantial sample size and thorough nature of the data gathering ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or limited subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology measured practical outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine works when administered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.

Learning about RSV and its threats

Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.

The infection triggers deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to breathe and feed effectively. Parents frequently observe their babies visibly struggling, their chests heaving as they attempt to draw adequate oxygen into their damaged lungs. Whilst the majority of babies get better with palliative treatment, a small but significant proportion perish from RSV-related complications yearly, making vaccination as prevention a critical public health objective for safeguarding the most vulnerable and youngest individuals in the population.

• RSV causes lung inflammation, resulting in serious respiratory problems in infants
• Approximately half of newborns catch the infection in their first few months of life
• Symptoms span from mild colds to life-threatening chest infections requiring hospitalisation
• Over 20,000 UK babies need serious hospital treatment for RSV annually
• Few infants succumb to RSV complications each year in the UK

Uptake rates and specialist advice

Since the RSV vaccine programme commenced in 2024, health officials have emphasised the significance of pregnant women getting their jab at the best time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for ensuring newborns benefit from the most robust immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies through the placenta.

The messaging from public health bodies remains clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.

Regional disparities in immunisation

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and availability of the jab. These regional differences demonstrate differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics shows consistently strong protection regardless of geographical location.

• NHS trusts rolling out diverse outreach initiatives to connect with expectant mothers
• Inconsistencies across regions in vaccine uptake rates in different parts of England demand focused enhancement
• Regional health providers tailoring initiatives to align with community needs and circumstances

Practical implications and parent viewpoints

The vaccine’s remarkable effectiveness delivers tangible benefits for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the launch of this safeguarding intervention, the 80% drop in admissions represents thousands of infants protected against serious illness. Parents no longer face the upsetting situation of watching their newborns gasping for air or difficulty feeding, symptoms that characterise critical RSV illness. The vaccine has markedly changed the picture of neonatal respiratory health, offering expectant mothers a active means to shield their most at-risk babies during those crucial first weeks.

For families like that of Malachi, whose serious RSV infection resulted in profound brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s promotion of the jab highlights the transformative consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely avoidable has offered substantial reassurance to women in pregnancy navigating their final trimester, transforming what was once an unavoidable seasonal threat into a manageable health risk.